Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline.

Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor (KPT-8602) in China and Macau for cancer. Both

Read the full 425 word article

User Sign In